Researchers at UCLA have developed a blood test using gene activity data from immune cells that helps predict the survival of advanced heart failure patients receiving mechanical circulatory support (MCS) devices.

Hispanic heart patients born abroad face a greater risk of dying from cardiovascular disease than their American-born counterparts, according to new research published in the Journal of the American Heart Association.

San Diego, Calif. — Renova™ Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s lead product candidate, RT-100 AC6 gene transfer (Ad5.hAC6), for the treatment of heart failure with reduced ejection fraction (HFrEF).

Cardiovascular deaths are up 2 percent from 2015 and have been identified as one of the fastest-growing health problems in the U.S., the United Health Foundation (UHF) reported this week in its 28th annual ranking report.

The U.S. flu season could be uncharacteristically harsh this winter, NPR reported this month—and that could have serious consequences for heart patients.

If you know the story, you know the stats—the eponymous character of Dr. Seuss’s "The Grinch Who Stole Christmas" starts the tale with a heart “two sizes too small” and ends it with one three times larger, thanks to Cindy Lou Who and her friends.

Patients who receive target or near-target doses of evidence-based medicine (EBM) are more likely to continue working after a heart failure hospitalization, according to a study of Danish individuals published Dec. 6 in JACC: Heart Failure.

Damage inflicted during non-cardiac surgery can reach heart cells and significantly raise a patient’s risk of mortality for up to one year after the procedure, according to research published this week in the American Heart Association journal Circulation.